Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18]fluorodeoxyglucose PET and CT comparison

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 3, 2007, Pages 224-234

  Mansueto, M ^a   Grimaldi, Adelmo ^a   Tobrica, A ^b   Pepe, G ^a   Giovacchini, G ^a   Messa, C ^a,c   Fazio, F ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

Computed tomography; Cost effectiveness; Decision trees; Emission computed; Lung neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INTERMETHOD COMPARISON; ITALY; LIFE EXPECTANCY; LUNG CANCER; LUNG LOBECTOMY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; WATCHFUL WAITING;

COST-BENEFIT ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HEALTH CARE COSTS; HUMANS; ITALY; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547503313     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Data (2005) are estimated by Reparto Epidemiologia dei Tumori del Centro Nazionale di Epidemiologia Sorveglianza e Promozione della Salute dell'Istituto Superiore di Sanitá. www.tumori.net.
2. Quint LE, Francis IR. Radiologic staging of lung cancer. J Thorac Imaging 1999;14:235-46.
3. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer: a meta-analysis. Ann Intern Med 2003;139:879-900.
4. Swensen SJ, Viggiano RW, Midthun DE, Muller NL, Sherrick A, Yamashita K et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000;214:73-80.
5. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999;213:530-6.
6. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nackaerts KL et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest 1997;112:1480-6.
7. Pieterman RM, Van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61.
8. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss MB et al. Staging non-small cell lung cancer by whole body positron emission topographic imaging. Ann Thorac Surg 1995;60:1573-81.
9. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-84.
10. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-32.
11. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-90.
12. Wahl R, Quint L, Greenough R, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG-PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.
13. 18 F-FDG PET versus nodule-enhancement CT. AJR Am J Roentgenol 2006; 187:1361-7.
14. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nucl Med 1996;37:1428-36.
15. Esnaola NF, Lazarides SN, Mentzer SJ, Kuntz KM. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. J Clin Oncol 2001;20:263-73.
16. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-25.
17. Weber W, Bulow H, Romer W, Prauer H, Gambhir SS, Schwaiger M. FDG-PET in solitary pulmonary nodules: a German cost-effectiveness analysis. J Nucl Med 1997;38 Suppl:245p.
18. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.
19. Müller A, Stratmann-Schöne D, Klose T, Leidl R. Overview of economic evaluation of positron-emission tomography. Eur J Health Econ 2002;3:59-65.
20. Patz EF, Goodman PC. Positron emission tomography imaging of the thorax. Radiol Clin North Am 1994;32:811-23.
21. Sloka JS, Hollett PD, Mathews M. Cost-effectiveness of positron emission tomography for non-small cel lung carcinoma in Canada. Med Sci Monit 2004;10:MT73-80.
22. Scott WJ, Shepherd J, Gambhir SS. Cost effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thor Surg 1998;66:1876-83.
23. Madar I, Hoh C, Figlin R, Holmes CE, Waters PF, Gambhir SS et al. Cost effective staging of non-small cell lung carcinoma by whole body PET-FDG imaging. J Nucl Med 1995;36 Suppl:139-53.
24. Gugiatti A, Grimaldi A, Rossetti C, Lucignani G, De Marchis D, Borgonovi E, Fazio F. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small cell lung cancer in Italy. Q J Nucl Med Mol Imaging 2004;48:49-61.
25. Drummond M, Stoddart G, Torrace G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
26. Drummond M, McGuire A. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press; 2001.
27. 18F-FDG PET) study. Nucl Med Commun 2005;26:831-7.
28. Gugiatti A, Rossetti C, Grimaldi A, Fazio F. Due esercizi di analisi decisionale sulla introduzione della PET nei noduli polmonari solitari e nello staging di pazienti con NSCLC. Mecosan 1999;31:37-48.
29. Raab SS, Hornberger J, Raffin T. The importance of sputum cytology in the diagnosis of lung cancer: a cost effectiveness analysis. Chest 1997;112:937-45.
30. Bournet B, Migueres I, Delacroix M, Vigoroux D, Bornet JL, Escourrou J et al. Early morbidity of endoscopic ultrasound: 13 years' experience at a referral center. Endoscopy 2006; 38:349-54.
31. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 2003;95:230-6.
32. Hartman GW, Hattery RR, Witten DM, Williamson B Jr. Mortality during excretory urography: Mayo Clinic experience. AJR Am J Roentgenol 1982;139:912-22.
33. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW et al. Cost effectiveness of FDG PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000;27:1598-609.
34. Deliberazione n. VIII/1375 del 14/12/2005. Determinazioni in ordine alla gestione del Servizio Socio Sanitario Regionale Lombardia per l'esercizio 2006.
35. Unitá organizzative Qualitá e appropriatezza dei servizi sanitari, 2005. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del servizio sanitario regionale e relative tariffe.
36. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sci 2004;7:43-9.
37. Van Tinteren H, Hoekstra OS, Smit EF, Verboom P, Boers M; PLUS Study Group. Toward less futile surgery in non-small cell lung cancer A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography. Control Clin Trials 2001;22:89-98.